NYSE:IVA

Inventiva Competitors

$14.44
-0.32 (-2.17 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.39
Now: $14.44
$14.89
50-Day Range
$12.55
MA: $14.34
$16.50
52-Week Range
$9.01
Now: $14.44
$19.06
Volume13,200 shs
Average Volume38,697 shs
Market Capitalization$557.82 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Inventiva (NYSE:IVA) Vs. NUVB, IBRX, BCAB, IMCR, CGEM, and EWTX

Should you be buying IVA stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Inventiva, including Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), Cullinan Oncology (CGEM), and Cricut (EWTX).

Nuvation Bio (NYSE:NUVB) and Inventiva (NYSE:IVA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Profitability

This table compares Nuvation Bio and Inventiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
InventivaN/AN/AN/A

Earnings and Valuation

This table compares Nuvation Bio and Inventiva's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
InventivaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Nuvation Bio and Inventiva, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
Inventiva10402.60

Nuvation Bio currently has a consensus target price of $17.40, suggesting a potential upside of 74.00%. Inventiva has a consensus target price of $27.3333, suggesting a potential upside of 89.29%. Given Inventiva's higher possible upside, analysts plainly believe Inventiva is more favorable than Nuvation Bio.

Summary

Nuvation Bio beats Inventiva on 2 of the 3 factors compared between the two stocks.

Inventiva (NYSE:IVA) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Inventiva and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InventivaN/AN/AN/A
ImmunityBioN/AN/AN/A

Earnings & Valuation

This table compares Inventiva and ImmunityBio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InventivaN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Inventiva and ImmunityBio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inventiva10402.60
ImmunityBio00103.00

Inventiva currently has a consensus price target of $27.3333, suggesting a potential upside of 89.29%. ImmunityBio has a consensus price target of $25.00, suggesting a potential upside of 48.19%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than ImmunityBio.

Summary

Inventiva beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

Inventiva (NYSE:IVA) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Inventiva and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InventivaN/AN/AN/A
BioAtlaN/AN/AN/A

Earnings & Valuation

This table compares Inventiva and BioAtla's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InventivaN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Inventiva and BioAtla, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inventiva10402.60
BioAtla00403.00

Inventiva currently has a consensus price target of $27.3333, suggesting a potential upside of 89.29%. BioAtla has a consensus price target of $58.00, suggesting a potential upside of 22.49%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than BioAtla.

Inventiva (NYSE:IVA) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Inventiva and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InventivaN/AN/AN/A
ImmunocoreN/AN/AN/A

Earnings & Valuation

This table compares Inventiva and Immunocore's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InventivaN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Inventiva and Immunocore, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inventiva10402.60
Immunocore01202.67

Inventiva currently has a consensus price target of $27.3333, suggesting a potential upside of 89.29%. Immunocore has a consensus price target of $54.3333, suggesting a potential upside of 53.18%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than Immunocore.

Summary

Inventiva beats Immunocore on 2 of the 3 factors compared between the two stocks.

Inventiva (NYSE:IVA) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Inventiva and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InventivaN/AN/AN/A
Cullinan OncologyN/AN/AN/A

Earnings & Valuation

This table compares Inventiva and Cullinan Oncology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InventivaN/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Inventiva and Cullinan Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inventiva10402.60
Cullinan Oncology01302.75

Inventiva currently has a consensus price target of $27.3333, suggesting a potential upside of 89.29%. Cullinan Oncology has a consensus price target of $48.25, suggesting a potential upside of 49.38%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than Cullinan Oncology.

Summary

Inventiva beats Cullinan Oncology on 2 of the 3 factors compared between the two stocks.

Inventiva (NYSE:IVA) and Cricut (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Inventiva and Cricut's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InventivaN/AN/AN/A
CricutN/AN/AN/A

Earnings & Valuation

This table compares Inventiva and Cricut's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InventivaN/AN/AN/AN/AN/A
CricutN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Inventiva and Cricut, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inventiva10402.60
Cricut0000N/A

Inventiva currently has a consensus price target of $27.3333, suggesting a potential upside of 89.29%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than Cricut.

Summary

Inventiva beats Cricut on 2 of the 2 factors compared between the two stocks.


Inventiva Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nuvation Bio logo
NUVB
Nuvation Bio
1.9$10.00-0.2%$2.18 billionN/A0.00Analyst Report
IBRX
ImmunityBio
1.7$16.87-10.8%$1.84 billionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
BioAtla logo
BCAB
BioAtla
1.5$47.35-0.7%$1.59 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$35.47-2.3%$1.53 billionN/A0.00Gap Down
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$32.30-5.8%$1.41 billionN/A0.00News Coverage
Gap Down
EWTX
Cricut
0.3$29.54-1.6%$1.41 billionN/A0.00News Coverage
KNTE
Kinnate Biopharma
1.7$31.55-0.5%$1.37 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.07-5.4%$1.33 billionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.12-9.2%$1.29 billionN/A0.00Gap Down
Vor Biopharma logo
VOR
Vor Biopharma
1.9$32.02-5.2%$1.19 billionN/A0.00Gap Down
FDMT
4D Molecular Therapeutics
1.1$37.69-7.7%$951.07 millionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.00-3.5%$948.89 millionN/A0.00News Coverage
Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$27.01-11.1%$948.02 millionN/A0.00Analyst Report
Insider Selling
Analyst Revision
News Coverage
Gap Down
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$28.32-0.1%$901.71 millionN/A0.00News Coverage
Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.50-6.1%$885.10 millionN/A0.00Analyst Downgrade
Gap Down
PHAR
Pharming Group
0.0$13.26-1.1%$845.93 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19-2.0%$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
FNCH
Finch Therapeutics Group
0.3$17.18-1.9%$809.95 millionN/A0.00News Coverage
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$13.22-6.1%$568.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
SGTX
Sigilon Therapeutics
1.4$17.76-1.7%$559.32 millionN/A0.00News Coverage
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.93-2.9%$475.62 millionN/A0.00News Coverage
Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.48-1.4%$456.41 millionN/A0.00Gap Down
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.13-4.7%$432.21 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$17.85-2.4%$406.23 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.8$9.93-2.3%$398.37 millionN/A0.00Analyst Revision
PRTG
Portage Biotech
0.0$29.23-2.0%$353.19 millionN/A0.00News Coverage
Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.83-1.0%$318.90 millionN/A-3.10
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.07-6.2%$300.24 millionN/A-2.79Gap Down
LBPH
Longboard Pharmaceuticals
1.9$16.00-0.0%$270.67 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.54-0.8%$262.47 millionN/A0.00News Coverage
IPA
ImmunoPrecise Antibodies
0.0$12.28-5.1%$234.78 millionN/A0.00News Coverage
Annovis Bio logo
ANVS
Annovis Bio
0.0$26.54-0.1%$184.37 millionN/A0.00
GANX
Gain Therapeutics
0.0$13.98-0.1%$158.41 millionN/A0.00News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$19.06-0.9%$156.39 millionN/A0.00Gap Down
LGVN
Longeveron
0.3$6.81-0.4%$127.40 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.09-9.2%$116.92 millionN/A0.00High Trading Volume
Analyst Revision
News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$4.64-3.2%$100.92 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.66-6.7%$61.20 millionN/A0.00Gap Down
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.62-0.4%$56.49 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.17-2.3%$51.40 millionN/A0.00Gap Down
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87-1.0%$45.59 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$4.66-1.3%$31.74 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.86-23.5%$24.03 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
0.0$45.90-19.8%$21.30 millionN/A0.00High Trading Volume
News Coverage
Gap Down
VYNT
Vyant Bio
0.0$4.02-4.0%$16.42 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$5.21-15.9%$4.02 millionN/A0.00High Trading Volume
Gap Down
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.78-5.3%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.94-0.7%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08-0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.